Novo Nordisk’s Canadian Patent CA 2601784 (Acylated GLP-1 Compounds), protecting Ozempic and Wegovy’s active ingredient, semaglutide, has lapsed. This event, linked to the non-payment of a maintenance fee, has drawn attention due to its potential to open the Canadian market to generic competition years earlier than anticipated. The competitive response was swift. Generic manufacturers quickly … Continue reading Canada’s Unexpected Opening for Ozempic Generics by 2026